Literature DB >> 9554908

How should different life expectancies be valued?

N Waugh, D Scott.   

Abstract

Mesh：

Year:  1998        PMID： 9554908      PMCID： PMC1113039          DOI： 10.1136/bmj.316.7140.1316

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  1 in total

1.  Modelling valuations for health states: the effect of duration.

Authors:  P Dolan
Journal:  Health Policy       Date:  1996-12       Impact factor: 2.980
  1 in total
  3 in total

Review 1.  Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review.

Authors:  A Clegg; D A Scott; P Hewitson; M Sidhu; N Waugh
Journal:  Thorax       Date:  2002-01       Impact factor: 9.139

2.  How should different life expectancies be valued? Existential model may be better than scale that uses quality adjusted life years.

Authors:  T Benson
Journal:  BMJ       Date:  1998-10-24

3.  Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment.

Authors:  N Starling; D Tilden; J White; D Cunningham
Journal:  Br J Cancer       Date:  2007-01-29       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.